UNSPSC 51141564: Nonapyrimine

This classification denotes an anticonvulsant agent with the molecular formula C15H24N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 322D5Y3Q0G, chemically known as 7h-pyrrolo(2,3-d)pyrimidine, 4-(nonylamino)- but generally known as nonapyrimine, which bears US NIH Compound Identifier 3047795. European Medicines Agency schedules Nonapyrimine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09350MIG.

UNSPSC 51141564 Nonapyrimine, a Commodity code, does not align with the recent state and local contract opportunities posted under this classification. The three most recent solicitations—a Seminole County, Florida naloxone and drug deactivation systems procurement; a Texas Health and Human Services Commission Request for Information on direct-to-manufacturer prescription programs; and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic pharmaceuticals and over-the-counter products—address pharmaceutical procurement, pharmacy benefit management, and community health supply chains, but none explicitly reference nonapyrimine or chemical compounds within its therapeutic class. The opportunities span public health departments, state HHS agencies, and cooperative purchasing alliances, indicating broad institutional interest in pharmaceutical sourcing and supply-chain efficiency, yet the mismatch between the code's nominal scope and actual recent buying activity suggests minimal recent state and local procurement specifically for nonapyrimine products.

Geographic activity concentrates in Florida, Texas, and Minnesota, where three distinct procurement vehicles have posted within the past six months. Seminole County's IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023, seeks 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries; Texas HHS's RFI HHS0017013, posted April 3, 2026, gathers market intelligence on direct-to-manufacturer pharmacy programs; and MMCAP's RFP S1070000015802, posted January 20, 2026, with a March 26, 2026 deadline, establishes multi-state contracts for generic pharmaceuticals and OTC products through authorized wholesalers. The code shows no clear demand signal for nonapyrimine procurement specifically, and business development efforts should verify whether state and local buying activity under this code reflects a data-classification mismatch or genuine procurement inactivity in this chemical category.